poisar

Stocks · News reference

Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer

Benzinga Newsdesk

— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FTH
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Faeth Therapeutics, Inc. (FTH)

    Filed: 2026-09-17 AccNo: 0001193125-26-394360 Size: 150 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    FTH